Pfizer接近7.3B交易 购买Metsera, 一个减重药物开发商, 进入繁荣的肥胖市场。 Pfizer nears $7.3B deal to buy Metsera, a weight-loss drug developer, to enter booming obesity market.

据报告,《金融时报》引用无名来源,称辉瑞公司接近于获得Metsera公司,这是一家在纽约的减重药品开发商,其交易价值73亿美元。 Pfizer is reportedly close to acquiring Metsera, a New York-based weight-loss drug developer, in a $7.3 billion deal, according to the Financial Times, citing unnamed sources. 这笔收购价值每股47.50美元,加上潜在的业绩支付,比Metsera最近的股价高出42.5%. The acquisition, valued at $47.50 per share in cash plus potential performance-based payments, represents a 42.5% premium over Metsera’s recent stock price. Pfizer放弃自己的肥胖药物Danuglipron, 是因为安全及可忍受性问题。 The move comes after Pfizer abandoned its own obesity drug, danuglipron, due to safety and tolerability issues. Metsera的首席候选人MET-097i显示,在中阶段试验中,体重平均下降11.3%。 Metsera’s lead candidate, MET-097i, showed an average 11.3% weight loss in mid-stage trials. 这项协议如果最终敲定,将标志着辉瑞进入迅速增长的肥胖治疗市场,预计到2030年代初将达到1500亿美元。 The deal, if finalized, would mark Pfizer’s entry into the rapidly growing obesity treatment market, projected to reach $150 billion by the early 2030s. 这两家公司均未确认报告,交易情况仍有可能改变。 Neither company has confirmed the reports, and the transaction remains subject to change.